Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
基本信息
- 批准号:10212240
- 负责人:
- 金额:$ 77.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Active ImmunizationAffinityAlternative TherapiesAntibodiesAntibody TherapyAntibody-mediated protectionBCG VaccineBacille Calmette-Guerin vaccinationBacteriaBeliefBindingCause of DeathCell WallCellsCellular ImmunityCharacteristicsCommunicable DiseasesComplexConjugate VaccinesDataDevelopmentDiseaseEpitopesFoundationsGoalsHeterogeneityHumanHumoral ImmunitiesImmuneImmune responseImmunoglobulin GImmunotherapyIn VitroKnowledgeLightingLocationMediatingMonoclonal AntibodiesMusMycobacterium tuberculosisNatural ImmunityOligosaccharidesPassive ImmunizationPhagocytosisPolysaccharidesProteinsPublic HealthPublishingRespiratory Tract InfectionsRoleSamplingSouth AfricanSpecificitySurfaceTestingTuberculosisTuberculosis VaccinesVaccinationVaccinesVirulence Factorsarmbasecapsuleexperimental studyextracellularglycosylationhuman monoclonal antibodiesimmunogenicin vivoinsightlipoarabinomannanmacrophagenovelpathogenpathogenic microbepolyclonal human antibodypreventprotective efficacyresponsetooltranslational studytuberculosis immunityvaccine developmentvaccine-induced antibodies
项目摘要
Abstract
Active tuberculosis (TB), a transmissible respiratory infection caused by uncontrolled Mycobacterium
tuberculosis (Mtb) infection, is worldwide one of the top 10 causes of death. To control this major global public
health problem alternative therapies and a more effective vaccine are urgently needed. The currently available
Bacillus Calmette-Guerin (BCG) vaccine has been in use for almost a century but provides insufficient
protection against TB. A major obstacle in the TB vaccine field is the limited understanding of the full breadth of
the immune components involved in the protection against TB. Currently, TB vaccine development is focused
on eliciting or boosting cell-mediated immunity, but increasing evidence suggests that antibodies also have a
role in the protection against TB. To gain a better understanding of the epitopes involved in human protection
and inducible by vaccination, detailed characterization and functional studies of human polyclonal and
monoclonal Abs (mAbs) to potentially protective epitopes are required. Antibodies to capsular and other
surface polysaccharides are protective against several microbial pathogens, including those with intracellular
location. Using novel glycan arrays our published and preliminary data show that human Abs to Mtb surface
glycans are highly heterogeneous in their binding specificity and differ in both their reactivity to oligosaccharide
motifs and their functions between BCG vaccination and/or controlled (latent) versus uncontrolled (TB) Mtb
infection. Our overarching hypotheses are: 1) Human Abs to AM are protective against Mtb, and 2) protection
by these Abs arises from reactivity to specific OS motifs within AM. Our specific aims are: 1. To generate and
characterize human polyclonal and mAbs to Mtb surface glycans; 2. To determine the effects of Mtb surface-
specific human Abs on macrophage functions; and 3. To establish the protective efficacy of Mtb surface-
specific human Abs in vivo. Our overarching goal is to identify key immunogenic Mtb glycotopes that render
Ab-mediated protection in humans. The information gained could fill a critical gap in the current knowledge of
TB immunity and inform new strategies for developing both vaccines and Ab-based immunotherapies against
TB.
摘要
活动性肺结核(TB),一种由不受控制的分枝杆菌引起的传染性呼吸道感染
结核病(Mtb)感染是世界范围内十大死亡原因之一。为了控制这个主要的全球公众
健康问题迫切需要替代疗法和更有效的疫苗。当前可用的
卡介苗(BCG)已经使用了近一个世纪,但提供的疫苗还不够
预防结核病。结核病疫苗领域的一个主要障碍是对结核病疫苗的全面了解有限
参与预防结核病的免疫成分。目前,结核病疫苗的开发是重点。
关于激发或增强细胞免疫,但越来越多的证据表明抗体也有
在预防结核病方面的作用。为了更好地了解人类保护所涉及的表位
并可通过接种疫苗、详细鉴定和人类多克隆和功能研究而诱导
需要针对潜在保护性表位的单抗。抗囊膜抗体和其他
表面多糖对几种微生物病原体有保护作用,包括细胞内的病原体。
地点。利用我们发表的和初步的数据显示,利用新型的多聚糖阵列,人的抗体到结核分枝杆菌表面
多聚糖具有高度的异质性,它们与低聚糖的反应能力不同。
卡介苗接种和/或控制(潜伏)与非控制(TB)结核分枝杆菌之间的基序及其功能
感染。我们的主要假设是:1)人类抗AM抗体对结核分枝杆菌有保护作用,2)保护作用
通过这些抗体,AM中的特定操作系统模体会发生反应我们的具体目标是:1.产生和
鉴定人多克隆抗体和单抗对结核分枝杆菌表面糖链的影响;2.确定结核分枝杆菌表面糖链的作用
人特异性抗体对巨噬细胞功能的影响;以及3.确定结核分枝杆菌表面抗体的保护作用。
体内特异的人抗体。我们的首要目标是确定关键的免疫原性结核分枝杆菌糖蛋白
AB介导的人体保护。所获得的信息可能会填补目前对
结核病免疫和为开发疫苗和基于抗体的免疫疗法提供新的战略
结核病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacqueline Michele Achkar其他文献
Jacqueline Michele Achkar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacqueline Michele Achkar', 18)}}的其他基金
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
- 批准号:
9803227 - 财政年份:2019
- 资助金额:
$ 77.3万 - 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
- 批准号:
10439644 - 财政年份:2019
- 资助金额:
$ 77.3万 - 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
- 批准号:
10525039 - 财政年份:2019
- 资助金额:
$ 77.3万 - 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
- 批准号:
10721412 - 财政年份:2019
- 资助金额:
$ 77.3万 - 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
- 批准号:
10119218 - 财政年份:2019
- 资助金额:
$ 77.3万 - 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
- 批准号:
10649613 - 财政年份:2019
- 资助金额:
$ 77.3万 - 项目类别:
Host biomarkers for M. tuberculosis infection activity in HIV-infected persons
HIV 感染者中结核分枝杆菌感染活动的宿主生物标志物
- 批准号:
9855497 - 财政年份:2016
- 资助金额:
$ 77.3万 - 项目类别:
Host biomarkers for M. tuberculosis infection activity in HIV-infected persons
HIV 感染者中结核分枝杆菌感染活动的宿主生物标志物
- 批准号:
9115881 - 财政年份:2016
- 资助金额:
$ 77.3万 - 项目类别:
Novel serological biomarker for rapid tuberculosis diagnosis
用于快速诊断结核病的新型血清学生物标志物
- 批准号:
9132479 - 财政年份:2013
- 资助金额:
$ 77.3万 - 项目类别:
Novel serological biomarker for rapid tuberculosis diagnosis
用于快速诊断结核病的新型血清学生物标志物
- 批准号:
8721846 - 财政年份:2013
- 资助金额:
$ 77.3万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 77.3万 - 项目类别:
Continuing Grant














{{item.name}}会员




